0914 Gilead Immunomedics
BioCentury & Getty Images

Deals

High takeout premium in $21B deal shows Gilead’s confidence in value of Immunomedics’ ADC

Gilead’s largest takeout ever adds to a string of cancer deals in 2020

Gilead’s largest takeout ever adds to a string of cancer deals in 2020.

Sep 14, 2020 | 9:55 PM GMT

For Gilead to derive value commensurate with the $21 billion it will pay to buy Immunomedics at more than double the biotech’s market cap, its first-in-class antibody-drug conjugate Trodelvy will have to gain approval and capture market share in indications beyond the one for which it has gained initial approval.

In its latest and largest in a series of cancer deals this year,

Read the full 1126 word article

How to gain access

Continue reading with a
two-week free trial.